All In Biotech

Drug Trial Radar · NCT00004061

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

A Randomized Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood

Last checked: Nov 20, 2026Latest source record: Jun 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Planned (sponsor's estimate)

Start

May 1999

Primary completion

May 2003

Study completion Dec 2009

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 25, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Primary purpose
Supportive care
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation. PURPOSE: Randomized phase II trial to study the effectiveness of biological therapy to reduce side effects in patients who are undergoing radiation therapy, chemotherapy, and peripheral stem cell transplantation in treating lymphoma or leukemia.

Conditions

  • Leukemia
  • Lymphoma
  • Oral Complications

Interventions

  • filgrastimBiological

  • paliferminBiological

  • cyclophosphamideDrug

  • etoposideDrug

  • ifosfamideDrug

  • peripheral blood stem cell transplantationProcedure

  • quality-of-life assessmentProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.